Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Yoshida, K. Articles by Nemeroff, C. B. Search for Related Content PubMed Citation Articles by Yoshida, K. Articles by Nemeroff, C. B. Depression Antidepressants Genetics

Prediction of Antidepressant Response to Milnacipran by Norepinephrine Transporter Gene Polymorphisms

OBJECTIVE: With a multitude of antidepressants available, predictors of response to different classes of antidepressants are of considerable interest. The purpose of the present study was to determine whether norepinephrine transporter gene (NET) and serotonin transporter gene (5-HTT) polymorphisms are associated with the antidepressant response to milnacipran, a dual serotonin/norepinephrine reuptake inhibitor. METHOD: Ninety-six Japanese patients with major depressive disorder were treated with milnacipran, 50–100 mg/day, for 6 weeks. Severity of depression was assessed with the Montgomery-Åsberg Depression Rating Scale. Assessments were carried out at baseline and at 1, 2, 4, and 6 weeks of treatment. The method of polymerase chain reaction was used to determine allelic variants. RESULTS: Eighty patients completed the study. The presence of the T allele of the NET T-182C polymorphism was associated with a superior antidepressant response, whereas the A/A genotype of the NET G1287A polymorphism was associated with a slower onset of therapeutic response. In contrast, no influence of 5-HTT polymorphisms on the antidepressant response to milnacipran was detected. CONCLUSIONS: The results suggest that NET but not 5-HTT polymorphisms in part determine the antidepressant response to milnacipran.

This article has been cited by other articles:

				M. J. Arranz and S. Kapur Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use? Schizophr Bull, November 1, 2008; 34(6): 1130 - 1144. [Abstract] [Full Text] [PDF]

				K. Yoshida, H. Higuchi, M. Kamata, H. Takahashi, K. Inoue, T. Suzuki, K. Itoh, and N. Ozaki The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine J Psychopharmacol, August 1, 2007; 21(6): 650 - 656. [Abstract] [PDF]

				C. J. Zheng, L. Y. Han, B. Xie, C. Y. Liew, S. Ong, J. Cui, H. L. Zhang, Z. Q. Tang, S. H. Gan, L. Jiang, et al. PharmGED: Pharmacogenetic Effect Database Nucleic Acids Res., January 12, 2007; 35(suppl_1): D794 - D799. [Abstract] [Full Text] [PDF]

				M. J. Ehret Pharmacogenomics of Antidepressant Medications Journal of Pharmacy Practice, December 1, 2006; 19(6): 342 - 352. [Abstract] [PDF]

				H. Kim, S.-W. Lim, S. Kim, J.-W. Kim, Y. H. Chang, B. J. Carroll, and D. K. Kim Monoamine Transporter Gene Polymorphisms and Antidepressant Response in Koreans With Late-Life Depression JAMA, October 4, 2006; 296(13): 1609 - 1618. [Abstract] [Full Text] [PDF]

				J. Kirchheiner, D. Grundemann, and E. Schomig Contribution of allelic variations in transporters to the phenotype of drug response J Psychopharmacol, July 1, 2006; 20(4_suppl): 27 - 32. [Abstract] [PDF]

				A. F. Schatzberg Recent Studies of the Biology and Treatment of Depression Focus, January 1, 2005; 3(1): 14 - 24. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us